Scott Wilhoit Net Worth

Scott Wilhoit biography

Scott L. Wilhoit serves as Chief Commercial Officer of the Company. Mr. Wilhoit joined Strongbridge in January 2017 and held roles of increasing responsibility, including Senior Vice President, Global Market Access, Patient Services and Advocacy, prior to his promotion to Chief Commercial Officer. Mr. Wilhoit has over 30 years of industry experience, much of which has been focused on commercializing products in a variety of rare disease categories. Most recently, Mr. Wilhoit served as Vice President, Market Access and Patient Services at Marathon Pharmaceuticals, where he designed and developed the access strategy for the company’s first commercial rare disease product. Previously, Mr. Wilhoit served as Vice President, Market Access and Health Services at PTC Therapeutics leading pre-launch market access strategic planning for the company’s Duchenne Muscular Dystrophy treatment. Prior to that, he served as Vice President, Pricing, Access and Patient Services at NPS Pharmaceuticals (acquired by Shire). Mr. Wilhoit has also served in a variety of positions with increasing responsibility with Clarus Therapeutics, Auxilium Pharmaceuticals, Biovail Corporation and Johnson & Johnson. Mr. Wilhoit served as a Field Artillery Officer in the U.S. Army and holds a BS in Criminology from Missouri Western State University.

How old is Scott Wilhoit?

Scott Wilhoit is 57, he's been the Chief Commercial Officer of Strongbridge Biopharma plc since 2019. There are 3 older and 6 younger executives at Strongbridge Biopharma plc. The oldest executive at Strongbridge Biopharma plc is David Gill, 65, who is the Independent Director.

What's Scott Wilhoit's mailing address?

Scott's mailing address filed with the SEC is 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE, PA, 19053.

Insiders trading at Strongbridge Biopharma plc

Over the last 7 years, insiders at Strongbridge Biopharma plc have traded over $0 worth of Strongbridge Biopharma plc stock and bought 2,670,648 units worth $8,846,818 . The most active insiders traders include Associates, L.L.C.Caxton Co..., Garheng Kong és Jeffrey W Sherman. On average, Strongbridge Biopharma plc executives and independent directors trade stock every 89 days with the average trade being worth of $593,478. The most recent stock trade was executed by David N Gill on 24 September 2020, trading 8,000 units of SBBP stock currently worth $17,040.

What does Strongbridge Biopharma plc do?

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Strongbridge Biopharma plc executives and stock owners

Strongbridge Biopharma plc executives and other stock owners filed with the SEC include:

• Frederic Cohen,
  Chief Medical Officer
• Robert Lutz,
  Chief Financial Officer
• John Johnson,
  Chief Executive Officer
• Marten Steen,
  Independent Director
• Garheng Kong,
  Lead Independent Director
• Richard Kollender,
  Chief Operating Officer
• Hilde Steineger,
  Independent Director
• Jeffrey Sherman,
  Independent Director
• David Gill,
  Independent Director
• Stephen Long,
  Secretary, Chief Legal Officer
• Scott Wilhoit,
  Chief Commercial Officer
• A Brian Davis,
  Chief Financial Officer
• Matthew Pauls,
  President & CEO
• Fredric J. Cohen,
  Chief Medical Officer
• Associates, L.L.C.Caxton Co...,